Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Boehringer Ingelheim
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07176975CT.gov A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers | — | Not Yet Recruiting | — | — | — |
NCT07492680CT.gov A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | — | Not Yet Recruiting | — | — | — |
NCT07404332CT.gov 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | — | Recruiting | — | — | — |
NCT07432295CT.gov Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | — | Recruiting | — | — | — |
NCT07276373CT.gov Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT05767684CT.gov Neoantigen Derived DCs as Cancer Treatment | — | Unknown | — | — | — |
NCT05919264CT.gov FOG-001 in Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05584670CT.gov A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05581719CT.gov A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | — | Terminated | — | — | — |
NCT05266612CT.gov Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | — | Recruiting | — | — | — |
Show 64 more trialsShow fewer
NCT05375084CT.gov SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | — | Terminated | — | — | — |
NCT05423262CT.gov A Study of TRK-950 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05150236CT.gov EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | — | Unknown | — | — | — |
NCT05076760CT.gov MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05176483CT.gov Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT04572451CT.gov Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma | — | Recruiting | — | — | — |
NCT05136937CT.gov A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05175235CT.gov Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | — | Unknown | — | — | — |
NCT04900818CT.gov Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04730349CT.gov A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer | — | Terminated | — | — | — |
NCT04731467CT.gov A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | — | Completed | — | — | — |
NCT04850755CT.gov A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies | — | Completed | — | — | — |
NCT04704154CT.gov A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | — | Completed | — | — | — |
NCT04591431CT.gov The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | — | Unknown | — | — | — |
NCT04570839CT.gov COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | — | Completed | — | — | — |
NCT04305249CT.gov Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies | — | Terminated | — | — | — |
NCT04350463CT.gov A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | — | Completed | — | — | — |
NCT04423029CT.gov A Study of DF6002 Alone and in Combination With Nivolumab | — | Completed | — | — | — |
NCT04311710CT.gov A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types | — | Terminated | — | — | — |
NCT04074967CT.gov Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | — | Active Not Recruiting | — | — | — |
NCT03838042CT.gov INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | — | Recruiting | — | — | — |
NCT04299880CT.gov Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | — | Completed | — | — | — |
NCT04200963CT.gov A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | — | Completed | — | — | — |
NCT03865082CT.gov Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | — | Active Not Recruiting | — | — | — |
NCT03980041CT.gov Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | — | Completed | — | — | — |
NCT04078295CT.gov A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | — | Active Not Recruiting | — | — | — |
NCT03953235CT.gov A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | — | Completed | — | — | — |
NCT03970382CT.gov A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | — | Suspended | — | — | — |
NCT04122625CT.gov Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 | — | Completed | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03647163CT.gov Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03447470CT.gov Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | — | Completed | — | — | — |
NCT03758781CT.gov IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03792724CT.gov Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors | — | Unknown | — | — | — |
NCT03570619CT.gov Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | — | Completed | — | — | — |
NCT03511222CT.gov Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03326258CT.gov Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | — | Withdrawn | — | — | — |
NCT03347123CT.gov A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | — | Terminated | — | — | — |
NCT03707808CT.gov Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab | — | Recruiting | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03251924CT.gov A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03195478CT.gov A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | — | Completed | — | — | — |
NCT03061188CT.gov Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | — | Completed | — | — | — |
NCT02901145CT.gov Nivolumab in Relapsed Pediatric Solid Tumors | — | Unknown | — | — | — |
NCT02817633CT.gov A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | — | Active Not Recruiting | — | — | — |
NCT02791334CT.gov A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | — | Completed | — | — | — |
NCT02702492CT.gov PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | — | Terminated | — | — | — |
NCT02705105CT.gov Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02663518CT.gov A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | — | Terminated | — | — | — |
NCT02628574CT.gov Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab | — | Completed | — | — | — |
NCT02426892CT.gov Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | — | Completed | — | — | — |
NCT02597036CT.gov A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02408861CT.gov Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | — | Terminated | — | — | — |
NCT02598960CT.gov An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | — | Completed | — | — | — |
NCT02488759CT.gov An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | — | Completed | — | — | — |
NCT02472977CT.gov Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | — | Terminated | — | — | — |
NCT02419417CT.gov Study of BMS-986158 in Subjects With Select Advanced Cancers | — | Completed | — | — | — |
NCT02476123CT.gov Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02423343CT.gov A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02118337CT.gov A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01968109CT.gov An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | — | Completed | — | — | — |
NCT01682135CT.gov A Study in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01629758CT.gov Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Boehringer Ingelheim | P2 | B · 60 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →